Tag: branch

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

PORT JEFFERSON, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Hanover Community Bank (“Hanover Bank”), the bank subsidiary of Hanover Bancorp (Nasdaq “HNVR”), is excited to announce the opening of its tenth branch, located in the historic and bustling village of Port Jefferson on Long Island. This expansion marks a significant step in Hanover Bank’s strategic growth, strengthening its commitment to serving both businesses and individual consumers across the Long Island region and beyond.

OAKDALE, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Oak Valley Community Bank, a wholly-owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), announced that Mariam Shah has joined the bank as Vice President, Branch Manager of the Lodi Branch which is located at 31 South School Street and is slated to open later this summer.

Discover Camfil's tailored clean air solutions for Austin's energy sector, for enhanced efficiency, sustainability, and compliance with advanced filtration systems.

MIDDLETOWN, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Orange Bank & Trust Company (the “Bank”), the banking subsidiary of Orange County Bancorp, Inc. (the “Company” - Nasdaq: OBT), is pleased to announce the promotion of Elizabeth “Liz” Jones, Chief Operating Officer, to Executive Vice President.

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.